NFKB1 and liver disorder: If NFκB is to be examined as a therapeutic target in liver diseases, interventions that employ either pathway-specific NFκB blockade or a moderate effect on NFκB activity will be essential to avoid the increase in hepatic injury associated with complete NFκB blockade26.